Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $23.4 million.

  • Compass Therapeutics' Net Cash Flow rose 3000.83% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 2736.57%. This contributed to the annual value of $19.3 million for FY2024, which is 27965.11% up from last year.
  • As of Q3 2025, Compass Therapeutics' Net Cash Flow stood at $23.4 million, which was up 3000.83% from -$18.2 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Net Cash Flow registered a high of $23.4 million during Q3 2025, and its lowest value of -$18.2 million during Q2 2025.
  • Over the past 3 years, Compass Therapeutics' median Net Cash Flow value was -$2.4 million (recorded in 2025), while the average stood at $1.0 million.
  • As far as peak fluctuations go, Compass Therapeutics' Net Cash Flow soared by 19864.47% in 2024, and later crashed by 33953.07% in 2025.
  • Compass Therapeutics' Net Cash Flow (Quarter) stood at -$6.2 million in 2023, then skyrocketed by 198.64% to $6.1 million in 2024, then skyrocketed by 282.01% to $23.4 million in 2025.
  • Its Net Cash Flow was $23.4 million in Q3 2025, compared to -$18.2 million in Q2 2025 and -$2.4 million in Q1 2025.